about
Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old ideaBeyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologiesNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerManagement of venous thromboembolism in patients with primary and metastatic brain tumors.The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomasPhase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancerA phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).Resolving Rivalries and Realigning Goals: Challenges of Clinical and Research Multiteam Systems.Increase in Cancer Center Staff Effort Related to Electronic Patient Portal Use.A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Predictors and intensity of online access to electronic medical records among patients with cancer.Impact of prior cancer on eligibility for lung cancer clinical trials.Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?Targeted therapies for lung cancer: clinical experience and novel agentsTemporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations.Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center.Patient comprehension and attitudes toward maintenance chemotherapy for lung cancerLooking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis.Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?Should criteria for inclusion in cancer clinical trials be expanded?ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancerImpact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.EGFR Inhibition in the Treatment of Non-Small Cell Lung CancerImpact of NCI-mandated scientific review on protocol development and content.Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition.Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.Stigma among patients with lung cancer: a patient-reported measurement modelCetuximab in combination therapy: from bench to clinic.Miscellaneous agents--cytotoxics and hormonal agents.Management and future directions in non-small cell lung cancer with known activating mutations.Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies.Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials.Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer.
P50
Q27011282-BCC07208-31E4-4D66-A7C2-2AED5410EE26Q28084029-01015542-5AAD-4BC8-B2F0-0026638E934DQ29620913-CD0BFC2F-3102-491E-A259-A690DB24257DQ33370485-8B0D4E5D-674B-4A00-9968-55B99CB6F47EQ33373291-E0C54633-594D-4E20-A621-54791C34E814Q33410020-CF9B28E8-0E06-4F04-BE80-AE3FBD3260B4Q33422932-E8EBFBB5-620B-451E-956A-57B61262FAC1Q33756587-FC461C13-0254-4ADF-99E9-AB5A05C83DA2Q33756763-552047DD-F6F9-4B78-A159-2E712DB19382Q33865475-5B84181E-0561-48FF-8E27-0B0EDCBDDDFEQ34168206-5DF0C256-2256-482D-9486-2FADF68B5824Q34736086-1E4EE3F5-3531-415F-BF09-1BAF32BBE4C6Q35473988-6463F871-C790-482E-8318-47D605F5ACAFQ35855354-7AC04F76-86B3-4DEC-AB01-BA0F0C2F85A2Q36054970-FCC4856B-106A-4AC1-BA7D-E2AD2E458826Q36064874-FB854D70-F47F-4BDD-91F0-1461A6071D52Q36218424-A06269D3-4EF1-444C-A0D0-FABC5D589CFFQ36236671-3B36F3AB-7B8D-4340-A392-09C26183A7E5Q36304283-6684309B-D6E6-4CAD-9AC9-67218734DD63Q36316513-DFDAF673-610E-420F-87FE-031551A06C65Q36677154-D9CC5CAD-1DD9-47BE-A9CD-9F22BC8F89F6Q36811784-81BFD246-85F3-459E-A8EE-1AF758DE1A67Q36816895-C04DDF02-63C8-44A6-A69E-BD8C5ADFCA44Q36820561-556CC2B8-67EA-4CFC-A3E9-0CA9A3D51207Q36823770-76C57A76-0A6A-478D-B58A-8E44F9FB4FCBQ36927086-025773A6-3ED0-4A55-95A5-359CFD3C6E4DQ36946100-F559F0AE-1C9F-409C-8D91-BF328A389B4DQ37240726-E60C09AD-46B9-42E4-BAFF-D6FC060371FEQ37429058-8568EDC3-474E-409F-9CF3-0F23B1F67CB3Q37444619-78BACFA0-595A-4087-B900-BE95F17A5CF7Q37506630-8B08B5A8-7500-4823-A458-EF18C289D9D4Q37583786-17B72D4E-165A-43DD-BC53-39557DD007BCQ37606816-1E724185-8A9B-49C9-88FF-69241DEE48F8Q37689025-D212138F-2846-4232-A989-83D91B038F74Q38060512-0FD142D7-8B00-4FB1-96DA-82DAFE751BD0Q38214303-B2B64645-FDB9-40A5-85E1-D04AE6D283F2Q38343677-7AAC33C6-850F-4576-B7A9-5B6CDA55B546Q38374064-9C8C730F-880E-4917-9394-397447C26970Q38409218-3F2026A2-F341-44C3-9DD1-BCCE6FBB0D09Q38423476-B8114D6D-4FF9-46E0-943B-D4C6E31ECF8A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David E. Gerber
@ast
David E. Gerber
@en
David E. Gerber
@es
David E. Gerber
@nl
David E. Gerber
@sl
type
label
David E. Gerber
@ast
David E. Gerber
@en
David E. Gerber
@es
David E. Gerber
@nl
David E. Gerber
@sl
prefLabel
David E. Gerber
@ast
David E. Gerber
@en
David E. Gerber
@es
David E. Gerber
@nl
David E. Gerber
@sl
P106
P1153
12775814500
P21
P31
P496
0000-0002-7812-6741